CoChat
Sign Up
Cited by 991Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and MetabolismCardiovascular Disease and Adiposity

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis

Li, Shanshan, Shin, Hyun Joon, Ding, Eric L., van Dam, Rob M.·2009·JAMA
DOI 10.1001/jama.2009.976
Open this paper in CoChat — free account

Abstract

CONTEXT: The association of obesity with development of type 2 diabetes may be partly mediated by altered secretion of adipokines by adipose tissue. Greater adiposity down-regulates secretion of adiponectin, an adipokine with anti-inflammatory and insulin-sensitizing properties. The strength and consistency of the relation between plasma adiponectin and risk of type 2 diabetes is unclear. OBJECTIVE: To systematically review prospective studies of the association of plasma adiponectin levels and risk of type 2 diabetes. DATA SOURCES: A systematic search of the MEDLINE, EMBASE, and Science Citation Index Expanded databases using adiponectin and diabetes and various synonyms and reference lists of retrieved articles up to April 10, 2009. STUDY SELECTION: We included prospective studies with plasma adiponectin levels as the exposure and incidence of type 2 diabetes as the outcome variable. DATA EXTRACTION: Two reviewers independently extracted data and assessed study quality. Generalized least-squares trend estimation was used to assess dose-response relationships. Pooled relative risks and 95% confidence intervals were calculated using random-effects models to incorporate between-study variation. RESULTS: Thirteen prospective studies with a total of 14 598 participants and 2623 incident cases of type 2 diabetes were included in the meta-analysis. Higher adiponectin levels were monotonically associated with a lower risk of type 2 diabetes. The relative risk of type 2 diabetes was 0.72 (95% confidence interval, 0.67-0.78) per 1-log microg/mL increment in adiponectin levels. This inverse association was consistently observed in whites, East Asians, Asian Indians, African Americans, and Native Americans and did not differ by adiponectin assay, method of diabetes ascertainment, duration of follow-up, or proportion of women. The estimated absolute risk difference (cases per 1000 person-years) per 1-log microg/mL increment in adiponectin levels was 3.9 for elderly Americans and 30.8 for Americans with impaired glucose tolerance. CONCLUSION: Higher adiponectin levels are associated with a lower risk of type 2 diabetes across diverse populations, consistent with a dose-response relationship.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.2009.976

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

See all 991

Related

Metadata

Authors
Li, S., Shin, H. J., Ding, E. L., & van Dam, R. M.
Affiliations
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2009-07-08
Volume
302
Issue
2
Pages
179
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2009.976
OpenAlex
W2041272089
Cited by
991
References
43
Citations by year
2026: 16 · 2025: 37 · 2024: 48 · 2023: 47 · 2022: 44 · 2021: 43 · 2020: 58 · 2019: 50 · 2018: 60 · 2017: 51 · 2016: 62 · 2015: 77 · 2014: 89 · 2013: 89 · 2012: 82
FWCI
49.46
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK4600)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
adiponectin, type 2 diabetes, plasma adiponectin levels, adipokines, obesity, insulin sensitivity, anti-inflammatory activity, dose-response relationship, impaired glucose tolerance, ethnic differences, diabetes risk
MeSH terms
Diabetes Mellitus, Type 2, Humans, Risk Factors, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review